Results 31 to 40 of about 2,530 (165)

Guía de recomendaciones para el manejo de brolucizumab [PDF]

, 2022
Brolucizumab; Intraocular inflammation; Patient managementBrolucizumab; Inflamación intraocular; Manejo del pacienteBrolucizumab; Inflamació intraocular; Maneig del pacientPurpose: Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and ...
Adán, Alfredo, Figueroa, Marta, Fonollosa, Alex, Gallego-Pinazo, Roberto, López Gálvez, María Isabel, Sararols, Laura   +5 more
core   +1 more source

Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe angiographic features of a case of delayed-onset retinal vascular occlusion and intraocular inflammation (IOI) following brolucizumab intravitreal injection (IVI).
Sentaro Kusuhara, Kyung Woo Kim, Akiko Miki, Makoto Nakamura   +3 more
doaj   +1 more source

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

BMC Health Services Research, 2022
Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula).
Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri   +3 more
doaj   +1 more source

Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report

BMC Ophthalmology, 2022
Background We present a case of retinal occlusive vasculitis following brolucizumab administration and the first report of optical coherence tomography angiography (OCTA) findings after treatment.
Eun Kyoung Lee, Baek-Lok Oh, Chang Ki Yoon, Un Chul Park   +3 more
doaj   +1 more source

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose [PDF]

, 2023
Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model.
Di Bin, Francesco, Lanzetta, Paolo, Sarao, Valentina, Veritti, Daniele   +3 more
core   +1 more source

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology
AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC). METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group.
Jung Yeon Joo, Yong Hyun Jun, Seong Taeck Kim   +2 more
doaj   +1 more source

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization

Scientific Reports, 2023
We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV).
Hidetaka Matsumoto, Junki Hoshino, Kosuke Nakamura, Hideo Akiyama   +3 more
doaj   +1 more source

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series

American Journal of Ophthalmology Case Reports, 2021
Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes
Debdulal Chakraborty, Jay U. Sheth, Subhendu Boral, Tushar K. Sinha   +3 more
doaj   +1 more source

The Role of Inflammation in Age-Related Macular Degeneration: Updates and Possible Therapeutic Approaches [PDF]

, 2022
Age-related macular degeneration (AMD) is a common retinal disease characterized by complex pathogenesis and extremely heterogeneous characteristics.
Aragona, Emanuela, Arrigo, Alessandro, Bandello, Francesco   +2 more
core   +1 more source

Brolucizumab for Neovascular Age-Related Macular Degeneration in Real-World Setting

IJRETINA (International Journal of Retina), 2023
Introduction: The mainstay treatment for neovascular AMD (nAMD) is intravitreal injections of anti-vascular growth factor (anti-VEGF) agents. Based on clinical trials, a newly developed anti-VEGF named brolucizumab showed noninferiority in anatomical and
Andi Marsa Nadhira, Ari Djatikusumo, Andi Arus Victor   +2 more
doaj   +1 more source